Literature DB >> 29349613

Tumor treating fields: a new approach to glioblastoma therapy.

Jonathan Rick1, Ankush Chandra2,3, Manish K Aghi2.   

Abstract

Glioblastoma is an aggressive brain malignancy with poor outcomes. Current standard of care involves surgery, radiotherapy and chemotherapy. Even with optimal treatment, 5-year survival rates are low. Many patients are unable to tolerate the considerable side effects that therapy involves and suffer from low quality of life. Anti-mitotic tumor treating fields have shown potential in treating glioblastoma with data suggesting that they prolong disease-free survival and overall survival. Novocure has marketed a device that generates these fields via externally placed electrodes. Incorporation of electric field therapy into GBM treatment has been somewhat slow, due to concerns about cost, practicality of its usage from a patient perspective, and hesitation of the medical and scientific community to embrace its unconventional mechanism. However, clinical trials have demonstrated this therapy has relatively minor side effects and high patient compliance. In this review, we explore the current state of this technology and discuss the benefits and limitations of tumor treating fields.

Entities:  

Keywords:  Cancer; Glioblastoma; Minimally invasive; Tumor treating fields

Mesh:

Year:  2018        PMID: 29349613     DOI: 10.1007/s11060-018-2768-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  48 in total

Review 1.  Tumor treating fields: a new standard treatment for glioblastoma?

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Opin Neurol       Date:  2015-12       Impact factor: 5.710

Review 2.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

3.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 6.  Standards of care and novel approaches in the management of glioblastoma multiforme.

Authors:  Andreas F Hottinger; Roger Stupp; Krisztian Homicsko
Journal:  Chin J Cancer       Date:  2014-01

7.  Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.

Authors:  Jay-Jiguang Zhu; Petya Demireva; Andrew A Kanner; Susan Pannullo; Maximilian Mehdorn; Nicholas Avgeropoulos; Andrea Salmaggi; Antonio Silvani; Samuel Goldlust; Carlos David; Alexandra Benouaich-Amiel
Journal:  J Neurooncol       Date:  2017-08-28       Impact factor: 4.130

8.  Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields).

Authors:  Eilon D Kirson; Rosa S Schneiderman; Vladimír Dbalý; Frantisek Tovarys; Josef Vymazal; Aviran Itzhaki; Daniel Mordechovich; Zoya Gurvich; Esther Shmueli; Dorit Goldsher; Yoram Wasserman; Yoram Palti
Journal:  BMC Med Phys       Date:  2009-01-08

Review 9.  Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.

Authors:  Timothy J Brown; Matthew C Brennan; Michael Li; Ephraim W Church; Nicholas J Brandmeir; Kevin L Rakszawski; Akshal S Patel; Elias B Rizk; Dima Suki; Raymond Sawaya; Michael Glantz
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

10.  Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series.

Authors:  George Ansstas; David D Tran
Journal:  Case Rep Neurol       Date:  2016-01-08
View more
  14 in total

1.  Current clinical management of patients with glioblastoma.

Authors:  Stephen Lowe; Krishna P Bhat; Adriana Olar
Journal:  Cancer Rep (Hoboken)       Date:  2019-09-04

2.  RNA modification patterns based on major RNA modifications define tumor microenvironment characteristics in glioblastoma.

Authors:  Ganglei Li; Yu Zhu; Jun Gu; Tiesong Zhang; Feng Wang; Kaiyuan Huang; Chenjie Gu; Kangli Xu; Renya Zhan; Jian Shen
Journal:  Sci Rep       Date:  2022-06-18       Impact factor: 4.996

3.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

Review 4.  Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.

Authors:  Kanawat Wiwatchaitawee; Juliana C Quarterman; Sean M Geary; Aliasger K Salem
Journal:  AAPS PharmSciTech       Date:  2021-02-11       Impact factor: 4.026

Review 5.  Link Between m6A Modification and Cancers.

Authors:  Zhen-Xian Liu; Li-Man Li; Hui-Lung Sun; Song-Mei Liu
Journal:  Front Bioeng Biotechnol       Date:  2018-07-13

6.  Human Biofield Therapy and the Growth of Mouse Lung Carcinoma.

Authors:  Peiying Yang; Yan Jiang; Patrea R Rhea; Tara Coway; Dongmei Chen; Mihai Gagea; Sean L Harribance; Lorenzo Cohen
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

Review 7.  Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.

Authors:  Denise Fabian; Maria Del Pilar Guillermo Prieto Eibl; Iyad Alnahhas; Nikhil Sebastian; Pierre Giglio; Vinay Puduvalli; Javier Gonzalez; Joshua D Palmer
Journal:  Cancers (Basel)       Date:  2019-02-02       Impact factor: 6.639

Review 8.  Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.

Authors:  Vilashini Rajaratnam; Mohammad Mohiminul Islam; Maixee Yang; Rachel Slaby; Hilda Martinez Ramirez; Shama Parveen Mirza
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639

9.  Electrochemical generation of microbubbles by carbon nanotube interdigital electrodes to increase the permeability and material uptakes of cancer cells.

Authors:  Mohammad Ali Khayamian; Shahriar Shalileh; Shohreh Vanaei; Mohammad Salemizadeh Parizi; Saeid Ansaryan; Mohammad Saghafi; Fereshteh Abbasvandi; Amirali Ebadi; Pouya Soltan Khamsi; Mohammad Abdolahad
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

10.  Formin-like 1 (FMNL1) Is Associated with Glioblastoma Multiforme Mesenchymal Subtype and Independently Predicts Poor Prognosis.

Authors:  Nayuta Higa; Yoshinari Shinsato; Muhammad Kamil; Takuro Hirano; Tomoko Takajo; Michiko Shimokawa; Kentaro Minami; Masatatsu Yamamoto; Kohichi Kawahara; Hajime Yonezawa; Hirofumi Hirano; Tatsuhiko Furukawa; Koji Yoshimoto; Kazunori Arita
Journal:  Int J Mol Sci       Date:  2019-12-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.